**Introduction:** There are currently no established guidelines in the prevention and treatment of autoimmune congenital heart block. Transplacental transfer of anti-Ro and anti-La antibodies can result in fetal congenital heart disease, with an incidence of 1-2%. Current recommendations include increased vigilance to detect abnormalities through the utilisation of fetal echocardiograms and obstetric sonograms. Despite investigations, however, it remains unclear which populations may benefit from preventative therapy.

**Case description:** We present a case of a 29 year old woman with undifferentiated connective disease who attended for fetal monitoring. Complete atrioventricular dissociation had been detected in the fetus at week 24 of her pregnancy. She additionally had, at the time of monitoring, developed a vasculitic rash affecting her feet in otherwise quiescent disease. She was diagnosed with juvenile connective tissue disease at 11 years of age. She presented with polyarthralgia, rash and positive autoantibodies. Her antibody profile was as follows: positive ANA titre \>1/640, antibodies to Ro and La, anti-cardiolipin antibodies had been present at disease presentation. Treatment with hydroxychoroquine was complicated by the development of a bull's eye maculopathy and was therefore discontinued. Her disease, however, was relatively well controlled with short courses of prednisolone. Her first pregnancy, at age 28, was complicated by a uterine perforation, which resulted in spontaneous abortion of the fetus. Prior to conceiving, her clinical disease activity was low -- she did not complain of any arthralgia, rash or systemic symptoms. Her ESR was 61, C-reactive protein \<5. Her ANA titre remained at 1/640, with positive Ro and La antibodies. Her double-stranded DNA antibodies were negative. Her C3 level remained low at 0.11 and C4 was normal at 1.11. A repeat antiphospholipid screen was negative but as she was deemed high-risk, aspirin was continued in this pregnancy. Fetal scanning had been undertaken at a specialist obstetric clinic in a tertiary centre. She was given high dose dexamethasone and consideration was given to the administration of intravenous immunoglobulin. Following further discussion, however, the plan was made to continue with the pregnancy without further immunomodulation. She has been counseled about the grave risk of perinatal morbidity and mortality and continues to be monitored with high vigilance.

**Discussion:** This case led to a review of the literature and best practice in high risk Ro and La antibody positive mothers. The use of high dose steroids remains controversial, despite several studies reporting the use of high dose dexamethasone or betamethasone. A large study of 175 fetuses with second or third degree heart block, where 67 were treated with steroids failed to demonstrate any difference in outcome compared with non-treated fetuses. Treatment was also deemed to be questionable in an older study in which 93 cases of fetal heart block treated in which no reversal of complete heart block was noted. Dexamethasone was given to our patient and is a useful discussion point here as some studies suggest there maybe some benefit in incomplete heart block -- is it better to offer the patient some form of treatment or avoid the potential side effects of controversial treatment? Hydroxychloroquine has been shown to reduce the chance of developing complete heart block and is safe in pregnancy. Given our patient's history of maculopathy, however, this was not an option and is unlikely to be utilized in future pregnancies. IVIG was considered in this case but not given. There are case reports where administration of IVIG has resulted in reversal to sinus rhythm in incomplete heart block; however there is no evidence supporting a role in established complete heart block. In terms of future pregnancies, two studies administered IVIG at a dose of 400 mg/kg failed to demonstrate any evidence in reducing recurrence of CHB and were terminated early. It also poses the question whether there is any evidence to administer immunoglobulins in any subsequent pregnancies, as the risk increases to 17-25% following the birth of one child with complete heart block.

**Key learning points:** Main learning points: Management of autoimmune congenital cardiac disease remains controversial. There is conflicting data on therapies once complete heart block has been established; studies have explored steroids, hydroxychloroquine, IVIG and plasma exchange. Advice and treatment for future pregnancies is important; currently this is on an individual case basis. Treatment is usually reserved for "high-risk" mothers with active disease or high titres of anti-phospholipid antibodies. Counseling the patient and their family is key as the psychological factors involved with extra monitoring and complications must be addressed by both rheumatologists and obstetricians. Learning objectives and key questions to be discussed at the conference 1. Review of the evidence behind these therapies 2. Is there a role for steroids? 3. Would this patient be eligible or offered preventative therapy in the future? 4. Should all antibody positive mothers be on hydroxychloroquine regardless of disease activity? 5. Updates and clinical trials
